Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer. Besides their anti-tumour efficacy, several PKIs have also shown radiosensitizing effects when combined with external beam radiation. | Combination of lutetium-177 labelled antiL1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775 A novel combination against human ovarian carcinoma